
## It's Time to STRATAFIX™

## The leader in barbed suture technology<sup>1</sup>



### STRATAFIX™ **Spiral** Knotless Tissue Control Devices

Unidirectional




#### **Plus Antibacterial Properties** Meta-analysis demonstrates 28% reduction in surgical site infection (SSI) risk with the use of triclosan-coated sutures2\*†‡ STRATAFIX Knotless Tissue Control V-Loc 180™ Devices are the **only** commercially STRATAFIX available knotless **Spiral Device** tissue control devices with antibacterial protection<sup>3-5</sup> The petri dish image is for illustrative purposes only, zone of inhibition testing results can vary. \*21 RCTs, 6462 patients, 95% CI: (14, 40%), P<0.001 †All triclosan-coated sutures in these RCTs were Ethicon Plus Antibacterial Sutures

(MONOCRYL® Plus Antibacterial [poliglecaprone 25] Suture, Coated VICRYL® Plus Antibacterial

[polyglactin 910] Suture, and PDS\* Plus Antibacterial [polydioxanone] Suture)

<sup>‡</sup>Meta-analysis only included traditional (non-barbed) sutures.



Features	STRATAFIX™ Knotless Tissue Control Devices	V-LOC™ Wound Closure Devices	Quill™ Knotless Tissue Closure Devices
Superior tissue holding strength	<b>√</b> 6	No <sup>7,8</sup>	No <sup>9-12</sup>
Antibacterial properties	<b>√</b> 3·5¶	No <sup>7,8</sup>	No <sup>9-12</sup>
Extended tensile wound holding strength	<b>√</b> 13,14	No <sup>7.8</sup>	<b>√</b> 10
Appropriate for use in fascia	<b>√</b> 6,13	No <sup>7,8</sup>	No <sup>9-12</sup>
Superior needle performance	<b>√</b> 15,16	No <sup>15,16</sup>	No <sup>15,16</sup>
Multiple anchor designs	<b>√</b> 13,14	No <sup>17</sup>	No <sup>18</sup>

<sup>§</sup>In porcine subcutaneous tissue





<sup>&</sup>quot;Specific to STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device.

<sup>\*</sup>Does not apply to all products in portfolio. Specific to STRATAFIX Symmetric PDS Plus Device, STRATAFIX™ Spiral MONOCRYL™ Plus Knotless Tissue Control Device, and STRATAFIX™ Spiral PDS™ Plus Knotless Tissue Control Device.

# With **STRATAFIX**™ Knotless Tissue Control Devices, Ethicon continues a century-long tradition of **leading the evolution** in wound closure technology

A full portfolio of knotless tissue control devices to address the needs of various tissue types competition can't match.

Features	STRATAFIX Knotless Tissue Control Devices	V-LOC™ Wound Closure Devices	Quill™ Knotless Tissue Closure Devices
Superior tissue holding strength	STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device demonstrated superior tissue holding strength compared to interrupted technique with Coated VICRYL® (polyglactin 910) Suture, continuous technique with PDS® II (polydioxanone) Suture, and V-Loc™ 180 Wound Closure Device	Inferior tissue holding strength when compared to STRATAFIX Symmetric PDS Plus Devices in subcutaneous tissue <sup>6</sup>	Inferior tissue holding strength compared to STRATAFIX Symmetric PDS Plus Device in subcutaneous tissue <sup>19</sup>
Antibacterial properties	STRATAFIX Knotless Tissue Control Devices with IRGACARE® MP (triclosan)-the only commercially available knotless tissue control devices with antibacterial protection <sup>13,14</sup>	V-LOC portfolio does not offer antibacterial products <sup>7,8</sup>	Quill™ portfolio does not offer antibacterial products <sup>9-12</sup>
Extended tensile strength	STRATAFIX™ Spiral PDO Knotless Tissue Control Device, STRATAFIX Spiral PDS Plus Device, and STRATAFIX Symmetric PDS Plus Device provide 6 weeks of tissue support <sup>13,14,20</sup>	The V-LOC™ 180 Absorbable Wound Cosure Device is not for use where prolonged (beyond 3 weeks) approximation of tissues under stress is required <sup>7</sup>	Quill™ PDO can be used in closures that require up to 6 weeks of tissue approximation <sup>10</sup>
Appropriate for use in fascia	STRATAFIX Symmetric PDS Plus Device is the only barbed suture appropriate for use in high-tension areas, such as fascia <sup>6,13</sup>	Warning in label states the safety and effectiveness of V-LOC has not been established for use in fascial closures <sup>7,8</sup>	Warning in label states the safety and effectiveness of Quill™ has not been established for use in fascial closures 9-12
Superior needle performance	Ethicon needles outperform competition due to: 15,16  • superior strength and ductility  • improved penetration  • reduced tissue trauma  • advanced silicone coating	Covidien needles require more penetration force versus Ethicon reverse-cutting and taper-point needles 15,16	Angiotech needles require more penetration force versus Ethicon reverse-cutting and taper-point needles 15,16
Multiple anchor designs	Available in spiral designs (bidirectional and unidirectional) and symmetric designs     Available in "cut" and "punched" technologies	<ul> <li>Available in spiral design only <sup>17</sup></li> <li>Only available in "cut" technologies</li> </ul>	<ul> <li>Available in spiral design only <sup>18</sup></li> <li>Only available in "cut" technologies</li> </ul>

Only Ethicon offers a barbed suture with Plus Antibacterial Technology that is appropriate for closing high-tension areas, such as fascia. 13\*

#### For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.

 $The third-party trademarks used herein are trademarks of their respective owners. {\tt *Refers} \ to {\tt STRATAFIX} \ Symmetric PDS \ Plus \ Device only.$ 

References: 1. Joshi P. Wound closure market and share October 2018 update. January 2019. Ethicon, Inc. 2. de Jonge SW, Atema JJ, Solomkin JS, Boermeester MA. Meta-analysis and trial sequential analysis of triclosan-coated sutures for the prevention of surgical-site infection. Br J Surg. 2017; 104(2):e118-e133. 3. Ming X, Rothenburger S, Yang D. In vitro antibacterial efficacy of Monocry Plus Antibacterial efficacy of Monocry Plus Antibacterial suture (poliglecaprone 25 with triclosan). Surg Infect (Larchmt). 2008;9(4):e151-e157. 5. Rothenburger S, Spangler D, Bhende S, Burkley D, In vitro antibination of coated Vicry Plus Antibiacterial efficacy of 190 with triclosan) using zone assays. Surg Infect (Larchmt). 2008;9(4):e151-e157. 5. Rothenburger S, Spangler D, Bhende S, Burkley D, In vitro antibination of coated Vicry Plus Antibiacterial efficacy of 190 with triclosan) using zone assays. Surg Infect (Larchmt). 2008;9(4):e151-e157. 5. Rothenburger S, Spangler D, Bhende S, Burkley D, In vitro antibination of coated Vicry Plus Antibiacterial efficacy of 190 with triclosan) using zone assays. Surg Infect (Larchmt). 2008;9(4):e151-e157. 5. Rothenburger S, Spangler D, Bhende S, Burkley D, In vitro antibination of coated Vicry Plus Antibiacterial 910 with triclosan) using zone assays. Surg Infect (Larchmt). 2008;9(4):e151-e157. 5. Rothenburger S, Spangler D, Bhende S, Burkley D, In vitro antibiacterial efficacy of Plus Antibiacterial Plus Antibiact



